An observational study in Relapse Leukemia, sponsored by huishengai. Completed at 1 site in China. Open to participants aged 9 Years to 67 Years. Per ClinicalTrials.gov, last updated 2016-07-13.
Sponsored by huishengai · Observational
The relapse leukemia patients after transplantation were divided into two groups randomly. Group D1: patients received first-donor stem cells infusion(DSI) treatment with or without chemotherapy; group D2: patients received second-donor DSI treatment with or without chemotherapy. The second donors were preferably donors who were genetically related and had more HLA-match locus. The re-induction chemotherapy regimen was primarily MAT(mitoxantrone, cytarabine, Teniposide ) for acute myeloid leukemia (AML) and VMCLD(vincristine, Teniposide, cyclophosphamide, L-Asparaginase, Dexamethasone) for acute lymphocytic leukemia (ALL), and no graft versus host disease(GVHD) prevention was conducted pre- and post- therapy.
Evaluation indications include bone marrow morphology,hematopoietic recovery (neutrophil and platelet), 100-day transplantation-related mortality (TRM), donor chimerism, acute GVHD, chronic GVHD, disease free survival (DFS), and overall survival (OS). The cut-time of the follow-up was Oct, 2013. DFS was defined as the time between the date of transplantation to the death or relapse. OS was defined as the time from diagnosis to death or to the last date of follow-up until Oct. 2013.
5,441 studies on the registry are indexed under Leukemia; 636 are open to participants now.
This study's enrollment of 20 is below the median of 120 across 744 observational studies indexed under Leukemia.
Browse Leukemia studies →This is the only study on the registry with huishengai as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Eligible patients were between 9 and 67 years of age with de novo diagnosed or treated-related Acute leukemia relapsed after HLA-matched hematological stem cell transplantation from Feb 2005 to Feb 2013.
Exclusion Criteria:
the original donor applicable patients were assigned to receive the first donor's stem cell treatment after G-CSF mobilization or combination chemotherapy
Biological: the first donor's stem cell
HLA-mismatched, the second donor's stem cell infusion
Biological: the second donor's stem cell
HLA-matched stem cell infusion
HLA-mismatched, the second donor's stem cell infusion
Number of Participants with graft versus host diseases
Time frame: 100 days
Time to Disease Progression
Time frame: 2 years
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.